Heat Biologics expands mid-stage study of HS-110 to include different PD-1 inhibitor

|About: Heat Biologics, Inc. (HTBX)|By:, SA News Editor

In an update for investors, Heat Biologics (NASDAQ:HTBX) says it has expanded its Phase 2 clinical trial evaluating HS-110 combo therapies in patients with non-small cell lung cancer to include another PD-1 inhibitor (Bristol-Myers Squibb's Opdivo and Merck's Keytruda are already involved) to treat patients at an earlier stage in their cancer.

It will present preliminary data from its other Phase 2 lung cancer study at the ASCO-SITC Clinical Immuno-Oncology Symposium on February 28. Enrollment should be completed next quarter.

Subscribe for full text news in your inbox